Mealey's (March 12, 2019, 8:48 AM EDT) -- WASHINGTON, D.C. — A case in which a drugmaker is trying to use an Indian tribe’s sovereign immunity to shield it from inter partes review (IPR) of its patents is a poor vehicle for the U.S. Supreme Court to decide the issue of tribal immunity for IPRs, respondent generic drugmakers tell the high court in a March 6 brief in opposition to a certiorari petition (Saint Regis Mohawk Tribe, et al. v. Mylan Pharmaceuticals Inc., et al., No. 18-899, U.S. Sup., 2019 U.S. S. Ct. Briefs LEXIS 837)....